GlobeNewswire Inc.··NaIN8bio to Unveil Gamma-Delta T Cell Advances at May R&D Day
IN8bio showcases gamma-delta T cell advances and glioblastoma survival data at May 2026 R&D Day and major medical conferences.
INABclinical dataautoimmune diseases
R&D Day
4 articlesGlobeNewswire Inc.··NaGlobeNewswire Inc.··NaMesoblast's Ryoncil Hits $30.3M in Q1 as First-Year Sales Near $100M Milestone
Mesoblast reports $30.3M quarterly sales for Ryoncil, its FDA-approved cell therapy for pediatric graft-versus-host disease, approaching $100M in first-year revenue.
MESOFDA approvalRyoncil®
GlobeNewswire Inc.··Mesoblast LimitedMesoblast Plans First R&D Day to Showcase Pipeline, New Cell Therapy Tech
Mesoblast Limited will host inaugural R&D Day April 8, 2026 in NYC, featuring Ryoncil commercialization updates and new cellular medicine technology.
MESORyoncil®cellular medicines
Benzinga··PrnewswireOrexo Charts New Course with R&D Day Showcase of AmorphOX Pipeline
Orexo invites investors to March 24 R&D Day in Stockholm to present post-Zubsolv strategy, featuring AmorphOX technology and pipeline programs OX640 and OX390.
ORXOYpipelinestrategic priorities